HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-06 · 44 (6)
DOI: 10.1161/atvbaha.123.319916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-06. Verfasst von Deping Kong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Cardiology (D.K., J. Liu, C.Z., H.C., X.Z., P.Z., L.Z., J. Li, Y.H.), The Second Xiangya Hospital of Central South University, Changsh…. Hauptthemen laut MEDLINE: HMGB2 Protein, Vascular Remodeling, Myocytes, Smooth Muscle, Disease Models, Animal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pulmonary hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vascular remodeling, which involves aberrant proliferation and apoptosis resistance of the pulmonary arterial smooth muscle cells (PASMCs), resembling the hallmark characteristics of cancer. In cancer, the HMGB2 (high-mobility group box 2) protein promotes the pro-proliferative/antiapoptotic phenotype. However, the function of HMGB2 in PH remains uninvestigated. METHODS: Smooth muscle cell (SMC)–specific HMGB2 knockout or HMGB2-OE (HMGB2 overexpression) mice and HMGB2 silenced rats were used to establish hypoxia+Su5416 (HySu)-induced PH mouse and monocrotaline-induced PH rat models, respectively. The effects of HMGB2 and its underlying mechanisms were subsequently elucidated using RNA-sequencing and cellular and molecular biology analyses. Serum HMGB2 levels were measured in the controls and patients with pulmonary arterial (PA) hypertension. RESULTS: HMGB2 expression was markedly increased in the PAs of patients with PA hypertension and PH rodent models and was predominantly localized in PASMCs. SMC-specific HMGB2 deficiency or silencing attenuated PH development and pulmonary vascular remodeling in hypoxia+Su5416-induced mice and monocrotaline-treated rats. SMC-specific HMGB2 overexpression aggravated hypoxia+Su5416-induced PH. HMGB2 knockdown inhibited PASMC proliferation in vitro in response to PDGF-BB (platelet-derived growth factor-BB). In contrast, HMGB2 protein stimulation caused the hyperproliferation of PASMCs. In addition, HMGB2 promoted PASMC proliferation and the development of PH by RAGE (receptor for advanced glycation end products)/FAK (focal adhesion kinase)-mediated Hippo/YAP (yes-associated protein) signaling suppression. Serum HMGB2 levels were significantly increased in patients with PA hypertension, and they correlated with disease severity, predicting worse survival. CONCLUSIONS: Our findings indicate that targeting HMGB2 might be a novel therapeutic strategy for treating PH. Serum HMGB2 levels could serve as a novel biomarker for diagnosing PA hypertension and determining its prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Cardiology (D.K., J. Liu, C.Z., H.C., X.Z., P.Z., L.Z., J. Li, Y.H.), The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai General Hospital (D.K., Z.D., Y.L., Q.Z.), Shanghai Jiao Tong University School of Medicine, China.
- Pathology (J. Lu), The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Guangdong, China (K.Y.).
- Department of Cardiovascular Medicine, The Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, China (L.Z.).
- Department of Cardiology, Rui Jin Hospital (L.L.), Shanghai Jiao Tong University School of Medicine, China.
ORCID-Profile: Deping Kong, Junmi Lu, Pu Zou, Yicheng Lv, Qingye Zeng, Lin Lu, Jiang Li, Yuhu He
Zitieren
APA
Kong, D., Liu, J., Lu, J., Zeng, C., Chen, H., Duan, Z., Yu, K., Zheng, X., Zou, P., Zhou, L., Lv, Y., Zeng, Q., Lu, L., Li, J., & He, Y. (2024). HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(6). https://doi.org/10.1161/atvbaha.123.319916
Vancouver
Kong D, Liu J, Lu J, Zeng C, Chen H, Duan Z, et al. HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(6). doi:10.1161/atvbaha.123.319916
BibTeX
@article{Kong2024,
author = {Kong, Deping and Liu, Jing and Lu, Junmi and Zeng, Cheng and Chen, Hao and Duan, Zhenzhen and Yu, Ke and Zheng, Xialei and Zou, Pu and Zhou, Liufang and Lv, Yicheng and Zeng, Qingye and Lu, Lin and Li, Jiang and He, Yuhu},
title = {HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {6},
doi = {10.1161/atvbaha.123.319916}
}
EUVIMED